Creative Touch Permanent Makeup and Aesthetics

Beta-defensins are not a single entity with a single story. The three members that dominate skin biology – hBD-1, hBD-2, and hBD-3 – differ in when they are expressed, what induces them, which pathogens they target, and precisely how they are suppressed in disease states. Getting that distinction right is what makes the beta-defensin science clinically useful rather than decoratively accurate.

hBD-1 is always present in healthy skin – constitutively expressed in keratinocytes as a baseline antimicrobial floor, independent of infection or inflammation. Its clinical significance is the discovery that in atopic dermatitis lesional skin, it can be epigenetically silenced through promoter DNA methylation – a fundamentally different suppression mechanism from the cytokine-driven reductions affecting its inducible siblings, and one that persists even when the inflammatory environment is resolved. hBD-2 is the AMP most directly connected to the skin microbiome: Staphylococcus epidermidis induces its expression through TLR2 signalling, creating a bidirectional circuit where commensals actively maintain the host’s peptide defence against pathogens. hBD-3 is the family’s most powerful member – active against gram-positive organisms including MRSA, gram-negatives, and fungi, effective at physiological salt concentrations where hBD-2 is partially inhibited, and capable of activating keratinocyte autophagy in a way that contributes to barrier homeostasis beyond any direct antimicrobial function. All three are suppressed in atopic dermatitis. All three are markedly elevated in psoriasis. And the mechanisms are as distinct as the molecules themselves.

Beta-defensins belong to the defensin superfamily – small, disulphide bond-stabilised cationic peptides characterised by a conserved three-stranded beta-sheet structure maintained by three intramolecular disulphide bonds. The disulphide bonds provide structural stability that alpha-defensins (the other major defensin class, concentrated in neutrophil granules and Paneth cells) lack in their equivalent form – giving beta-defensins better tolerance of the variable ionic environments of the skin surface without losing antimicrobial activity. They are expressed primarily by epithelial cells: keratinocytes are the dominant source in skin, supplemented by sebocytes, sweat gland epithelium, and hair follicle cells at specific anatomical sites. ^[2]

The three members most relevant to skin biology – hBD-1, hBD-2, and hBD-3 – are often grouped together as “the beta-defensins” in a way that obscures how different they actually are. Their expression patterns, regulatory inputs, downstream targets, and disease-state behaviour are all distinct. They are worth understanding individually.

hBD-1: the constitutive floor

hBD-1 is the baseline. Unlike its inducible siblings, hBD-1 expression does not require an infection, an injury, or an inflammatory stimulus. Keratinocytes produce it continuously, throughout the stratum spinosum and granulosum, in healthy skin at sites where no pathogen challenge is occurring. It is present at the skin surface as a constitutive antimicrobial tone – the AMP equivalent of a standing patrol rather than a rapid response unit.

Its antimicrobial spectrum includes gram-negative bacteria and Candida species, but its activity against gram-positive organisms including S. aureus is modest compared to hBD-2 and hBD-3. For years, hBD-1 was characterised primarily as a structural baseline – present, functional, but less potent than the inducible members. A more important story emerged with the discovery that hBD-1 can be epigenetically silenced in atopic dermatitis lesional skin. ^[5]

Epigenetic silencing in AD: the mechanism that doesn’t reverse with the inflammation.

A 2018 study (Noh et. al, 2018) established that the hBD-1 gene promoter contains CpG dinucleotide methylation sites – specifically CpG 3 and CpG 4 – that are significantly more methylated in AD lesional skin compared with both non-lesional AD skin and healthy control skin. Promoter methylation at these sites reduces transcriptional access to the DEFB1 gene, suppressing hBD-1 expression at the epigenetic level rather than through cytokine signalling or receptor inhibition. ^[5]

This distinction matters clinically. The cytokine-driven suppression of hBD-2 and hBD-3 in AD – mediated by IL-4 and IL-13 reducing IL-17-driven induction – is, in principle, reversible: resolve the Th2 inflammatory environment, and the cytokine suppression lifts. Epigenetic DNA methylation at the hBD-1 promoter does not automatically reverse when the inflammation clears. The mark persists in the lesional epidermis independently of the inflammatory environment that, in all probability, drove the methylation in the first place. The practical consequence is that a client whose AD has been successfully de-inflamed – whose lesional skin looks quiet and is no longer actively reactive – may still have epigenetically suppressed hBD-1 expression in the previously affected tissue. ^[5]

No current clinical treatment directly targets DEFB1 promoter demethylation in skin. This is not a gap the entity can close with a treatment recommendation – but understanding it changes expectations. Post-AD skin that is histologically quiescent but shows persistent S. aureus colonisation may be carrying an epigenetic AMP deficit that outlasts the obvious inflammation. The management implication is supporting the other AMP production routes – inducible hBD-2 and hBD-3 through microbiome and vitamin D strategies – rather than expecting hBD-1 function to have fully restored. ^[1]

hBD-2: the microbiome bridge

hBD-2 is the most extensively studied beta-defensin in skin – and the one whose biology most directly illustrates the bidirectional relationship between the microbiome and AMP defence described in the parent entity. It is not constitutively expressed. It requires induction.

Induction routes. Three primary pathways drive hBD-2 expression in keratinocytes:

TLR2 ligation by commensal bacteria. Staphylococcus epidermidis expresses lipoteichoic acid and lipoproteins in its cell wall that are recognised by TLR2 on keratinocytes. This TLR2 activation – at the low, homeostatic bacterial densities of healthy skin colonisation – drives NF-κB nuclear translocation and hBD-2 transcription. The circuit is continuous in healthy skin: S. epidermidis presence at normal colonisation levels maintains a background hBD-2 tone that is disproportionately effective against S. aureus, which has not developed the same tolerance to beta-defensins that S. epidermidis has acquired through co-evolution. ^[4]

IL-17A and IL-22 via NF-κB and JAK-STAT. IL-17A is a potent hBD-2 inducer – which is why hBD-2 is markedly elevated in psoriasis (a strongly Th17-driven condition) and substantially reduced in AD (where IL-17 activity is suppressed by the dominant Th2/IL-4/IL-13 environment). This cytokine regulation of hBD-2 creates the striking mirror image between psoriasis and AD: the same peptide overexpressed in one and deficient in the other, driven by opposite ends of the Th1/Th17 versus Th2 cytokine spectrum. ^[1]

Vitamin D receptor activation. The hBD-2 gene contains a directly confirmed vitamin D response element (VDRE). 1,25-dihydroxyvitamin D3 drives hBD-2 transcription in keratinocytes, though the pathway involves suppression of the IL-4/IL-13-mediated inhibitory signal rather than simple direct promoter binding. VDR activation simultaneously supports hBD-2 expression and reduces the Th2 signalling that was suppressing it – a dual mechanism that makes vitamin D particularly effective at restoring hBD-2 in the AD context where both VDR drive and Th2 suppression are needed. ^[1]

hBD-2 and barrier protection: the LAMB1 mechanism.

Beyond direct antimicrobial activity, hBD-2 protects the keratinocyte barrier against S. aureus V8 serine protease through an indirect mechanism established in a 2023 study. S. aureus V8 protease (GluSE/SspA) degrades extracellular matrix proteins, disrupting the structural integrity of the epidermis and facilitating bacterial penetration. A 2023 Nature Scientific Reports study established that hBD-2 treatment upregulates LAMB1 (laminin beta-1 chain) expression in keratinocytes – reinforcing the extracellular matrix architecture that V8 protease is targeting. ^{[7] [7]}

This is a mechanistically distinct protective function: hBD-2 is not killing the S. aureus organism in this pathway, nor directly inhibiting the protease. It is remodelling the keratinocyte’s structural environment to be more resistant to the protease’s destructive activity. A structural defence operating in parallel with the antimicrobial one. In AD skin where hBD-2 is suppressed, this structural reinforcement function is also absent – which is part of why S. aureus V8 protease can achieve such extensive filaggrin and corneodesmosomal degradation in lesional AD skin. The antibacterial and the structural protective functions fail together. ^{[7] [9]}

hBD-3: broad-spectrum, salt-resistant, and beyond antimicrobial

hBD-3 is the most potent antimicrobial member of the skin-relevant beta-defensin family, and in one important way it outperforms both hBD-1 and hBD-2: it maintains full antimicrobial activity at physiological salt concentrations. hBD-2 – like many cationic AMPs – shows reduced activity when sodium chloride concentrations approach physiological levels (~150 mmol/L), because salt ions compete with the peptide for electrostatic binding to the bacterial membrane surface. hBD-3’s higher cationic charge density allows it to overcome this competition, making it the beta-defensin most relevant to infection scenarios involving tissue fluid, wound exudate, and the aqueous environments of deeper epidermal layers. ^[2]

Its antimicrobial spectrum is the broadest of the three: gram-positive bacteria including S. aureus and MRSA, gram-negative bacteria, and fungi including Candida albicans. The MRSA activity is clinically significant – hBD-3 kills methicillin-resistant strains at concentrations achievable in healthy skin, positioning it as a relevant defence against the pathogen that antibiotic treatment has the most difficulty clearing. ^[8]

Autophagy activation: the function that goes beyond the membrane.

The most mechanistically distinctive property of hBD-3 is its ability to activate autophagy in keratinocytes – a function that has nothing to do with bacterial membrane disruption and everything to do with cellular homeostasis. A 2022 Journal of Clinical Investigation study established that hBD-3 attenuates AD-like inflammation through autophagy activation in keratinocytes, clearing the accumulated damaged proteins, misfolded structural components, and dysfunctional organelles that accumulate in the Th2 cytokine environment of atopic skin. ^[6]

Autophagy is the cell’s own clearance and recycling system. In the chronically inflamed keratinocytes of AD lesional skin, this system is overwhelmed – protein damage accumulates faster than basal autophagy can clear it, contributing to the cellular dysfunction that impairs differentiation, barrier protein production, and normal desquamation. hBD-3’s autophagy activation effectively provides cellular housekeeping support in parallel with its antimicrobial activity. ^[6]

This function connects hBD-3 to the broader barrier homeostasis story in a way that its antimicrobial framing alone would not suggest. The same peptide that is defending against MRSA at the skin surface is, within keratinocytes, maintaining the cellular health that underlies normal barrier protein production. When hBD-3 is suppressed in AD, both functions are lost together.

hBD-3 in post-procedural wound contexts. The combination of broad-spectrum antimicrobial activity (including MRSA coverage), salt-resistance, and autophagy-driven cellular homeostasis makes hBD-3 the most wound-relevant of the three beta-defensins. At fresh barrier breach sites – after microneedling, ablative laser, or any energy-based procedure producing epidermal disruption – restoring hBD-3 expression at the wound edge supports both pathogen defence and cellular clearance of the damage that the treatment itself produced. This is a legitimate mechanistic rationale for post-procedural interventions that stimulate NF-κB-driven hBD-3 induction, including CAP.

The condition spectrum: psoriasis vs atopic dermatitis

Beta-defensin expression across skin conditions shows the same striking inverse relationship noted for LL-37 – but the mechanistic explanation for each direction is worth examining precisely.

In psoriasis, all three beta-defensins are substantially elevated. The IL-17A and IL-22-rich Th17 environment is a powerful inducer of hBD-2 and hBD-3 through NF-κB and JAK-STAT pathways. This makes psoriatic skin remarkably resistant to S. aureus infection – a well-documented clinical observation. The elevated AMPs are not beneficial in psoriasis overall; they contribute to the self-sustaining inflammatory loop where excessive hBD-2 and hBD-3 activate plasmacytoid dendritic cells alongside LL-37/DNA complexes, deepening the Th17 amplification. The AMPs become participants in the autoimmune pathology. ^[1]

In atopic dermatitis, all three are suppressed – but through different mechanisms for each:

• hBD-1: epigenetic promoter methylation (DEFB1 CpG 3/4) in lesional skin – the mechanism that doesn’t reverse with inflammation resolution ^[5]
• hBD-2: Th2/IL-4/IL-13-driven suppression of IL-17-dependent induction; reduced S. epidermidis diversity removing TLR2 stimulation; reduced VDR activity from vitamin D insufficiency – three parallel suppressors ^[1]
• hBD-3: same Th2 cytokine suppression as hBD-2 plus the cellular autophagy dysfunction that its own absence perpetuates – a self-reinforcing loop where hBD-3 loss impairs the cellular clearance that would otherwise help recover hBD-3 expression ^[6]

The multi-mechanism nature of beta-defensin suppression in AD is the clearest argument against any single-intervention approach to restoring AMP function in atopic presentations. Each suppression route requires a different corrective strategy, and some – particularly the hBD-1 epigenetic silencing – have no direct corrective treatment currently available.

Vitamin D co-ordination across all three

Vitamin D receptor activation supports expression of all three beta-defensins, though with varying directness. hBD-2 has the most direct VDR connection, with a confirmed VDRE in its gene promoter. hBD-1 and hBD-3 induction by vitamin D is more indirect – mediated through VDR-driven suppression of the IL-4/IL-13 inhibitory environment and VDR-mediated enhancement of keratinocyte differentiation capacity. ^[1]

The clinical consequence is consistent: vitamin D sufficiency supports the entire beta-defensin family simultaneously, acting as a positive regulatory signal across multiple expression mechanisms. Deficiency suppresses the family from multiple angles at once – directly through VDRE-dependent hBD-2 reduction, and indirectly through reduced keratinocyte differentiation capacity and reduced Th2 suppression that allows IL-4/IL-13 inhibitory signalling to dominate. For clients with AD, correcting vitamin D to 75–100 nmol/L serum 25(OH)D is not merely a general health recommendation. It is specifically restoring a regulatory signal that the skin’s beta-defensin production system depends on. ^[1]